Spectral AI Provides 2023-2024 Annual Revenue Guidance
The Company recently announced the largest contract in its history, an award from the
- Research & Development Revenue (“Revenue”) for FY2023 is expected to approximate
- Revenue for FY2024 is expected to approximate
“We are on the cusp of delivering a distinct, cutting-edge AI-driven wound healing assessment platform with the potential to significantly improve the current standard of care across multiple indications,” said
The Company noted that the financial guidance for FY2024 does not reflect the material financial contributions it expects would result from the commercialization of DeepView® for DFU and 3D wound measurement following the receipt of necessary regulatory clearances. As previously disclosed, the Company has received regulatory approval for the DeepView SnapShot® device and the Company will now seek the approval of its integrated AI application to obtain both UKCA and FDA approval for the commercialization of the complete DeepView SnapShot® System in
“We believe we are in the best position in our history to deliver significant value for patients dealing with acute and chronic wound conditions, physicians and health systems that are challenged with effectively and cost-efficiently managing these conditions, and, of course, our shareholders,”
About Spectral AI
Spectral AI, Inc. is a
Forward Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions, or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the
VP Marketing and Commercialization
Source: Spectral AI, Inc.